Analyst ratings and price targets can significantly influence investor sentiment and stock price. The reiteration of an Outperform rating and a $24 price target by Wedbush analyst Robert Driscoll suggests a positive outlook for Janux Therapeutics, which could lead to an increase in its stock price in the short term.